Aastrom Biosciences Financial Statements
Aastrom Biosciences Financial Information
| Company Type | Public Headquarters |
|---|---|
| Fiscal Year-End | June |
| Annual Report | Company Web Site |
| Investor Relations | Company Web Site |
This data is provided as per license from EDGAR Online
Aastrom Biosciences Income Statement
| 2007 | 2006 | 2005 | |
|---|---|---|---|
| Revenue ($ mil.) | 0.7 | 0.9 | 0.9 |
| Gross Profit ($ mil.) | 0.7 | 0.9 | 0.8 |
| Operating Income ($ mil.) | (19.5) | (17.7) | (12.4) |
| Total Net Income ($ mil.) | (17.6) | (16.5) | (11.8) |
| Diluted EPS (Net Income) | (0.15) | (0.15) | (0.13) |
Aastrom Biosciences Quarterly Statements
| Quarter Ending Dec 07 | Quarter Ending Sep 07 | Quarter Ending Jun 07 | |
|---|---|---|---|
| Revenue ($ mil.) | 0.1 | 0.1 | 0.2 |
| Gross Profit ($ mil.) | -- | -- | 0.1 |
| Operating Income ($ mil.) | (5.5) | (5.4) | (5.2) |
| Total Net Income ($ mil.) | (5.2) | (5.1) | (4.8) |
| Diluted EPS (Net Income) | (0.04) | (0.04) | (0.04) |
Aastrom Biosciences Financial Ratios
| Company | Industry Median |
Market Median1 |
|
|---|---|---|---|
| Price/Sales Ratio | 89.43 | 3.69 | 1.58 |
| Price/Earnings Ratio | -- | 15.88 | 15.68 |
| Price/Book Ratio | 1.62 | 2.70 | 1.50 |
| Price/Cash Flow Ratio | -- | 11.61 | 9.70 |
1 Public companies trading on the New York Stock Exchange, the American Stock Exchange, and the NASDAQ National Market.
Detailed Aastrom Biosciences Financial Ratios
Aastrom Biosciences Competitive Intelligence
| Baxter | Cytori Therapeutics | Johnson & Johnson | |
|---|---|---|---|
| Annual Sales ($ mil.) | 11,263.0 | 6.0 | 61,095.0 |
| Employees | 46,000 | 143 | -- |
| Market Cap ($ mil.) | 38,475.7 | 182.8 | 182,285.9 |
Competitive Landscape
